Scorr-Insert
X

Find Approved Drugs for Infections and Infectious Diseases in Clinical Development in ISRAEL

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxycillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: HealthCare Royalty Partners

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing February 25, 2020

            Details:

            The non-dilutive financing will support the acquisition of rights to Movantik® from AstraZeneca, the planned U.S. launch of Talicia® this quarter and the ongoing promotion of Aemcolo®.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Omeprazole Magnesium,Amoxycillin,Rifabutin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Entera Health

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Termination Agreement January 21, 2020

            Details:

            RedHill provided a notice of termination to Entera Health regarding the license agreement for EnteraGam® and the co-promotion agreement with Advanz Pharma Corp. for Donnatal® will not be renewed.